📅 PUBMED DAILY TRIAGE — 2026-04-14

Window: 2026-04-13T09:00:00Z → 2026-04-14T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~95 candidates across topics | Candidates evaluated: 20 kept High priority: 1 | Standard: 14 | Low/archive: 5 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Novel Therapeutics / Rare Diseases High Unmet Need

TR-2026-04-14-001 · [PMID 41975092] · Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor · 8/10 · 🟠 NOVEL_TREATMENT Why it matters: This Nature Microbiology paper adds a new confirmed case to the rare series of HIV functional cures achieved via HSCT from a donor homozygous for the CCR5Δ32 mutation (the "Oslo patient"), building the evidence base for this curative approach. Authors: Myhre AE et al. DOI: 10.1038/s41564-026-02304-8

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

• TR-2026-04-14-002 [PMID 41975247] · Impact of survivorship care on burden of disease among Hodgkin lymphoma survivors · 7/10 · Public Health | Dutch multi-center cohort, JNCI — structured survivorship care reduces long-term morbidity in Hodgkin survivors · DOI: 10.1093/jnci/djag080
• TR-2026-04-14-006 [PMID 41975153] · Targeting HERV-K102 envelope elicits pyroptosis as novel AML therapeutic strategy · 5/10 (capped, preclinical) · Treatment Innovation | Novel HERV-K102 antigen target for AML pyroptosis; raw score 8 before non-human cap · Blood Res
• TR-2026-04-14-007 [PMID 41974595] · Circulating tumor cells in multiple myeloma: from peripheral clues to central insights · 5/10 · Diagnostics | Review, Am J Hematol; CTC utility as minimally invasive MM monitoring · DOI: 10.1002/ajh.70326

Early Cancer Detection / Liquid Biopsy

• TR-2026-04-14-003 [PMID 41974993] · KLK7/KLK10 and desmoglein 3 upregulated in early pancreatic cancerous lesions · 7/10 · Early Detection | Novel candidate biomarkers for pancreatic cancer early detection; Mayo Clinic-affiliated group; Sci Rep · DOI: 10.1038/s41598-026-48628-7
• TR-2026-04-14-004 [PMID 41973904] · Enzymatic cascade-powered urinary diagnostics for visual cancer monitoring · 7/10 · Diagnostics | ACS Nano proof-of-concept — non-invasive, low-cost urinary cancer monitoring platform · DOI: 10.1021/acsnano.6c00255

Precision Oncology / Genomic Medicine

• TR-2026-04-14-005 [PMID 41975179] · Multimodal omics dissects lymph node metastasis origin factors in NSCLC · 7/10 · Genomics/Precision Medicine | Nat Commun; mechanistic targets for NSCLC LN metastasis mapped via multimodal profiling · DOI: 10.1038/s41467-026-71819-9
• TR-2026-04-14-008 [PMID 41975017] · Multidisciplinary management of meningiomas in the era of precision oncology · 6/10 · Genomics/Precision Medicine | Nat Rev Clin Oncol; precision oncology framework for underserved CNS tumor · DOI: 10.1038/s41571-026-01148-9
• TR-2026-04-14-009 [PMID 41975095] · Cas12f ortholog characterization for enhanced genome editing efficiency · 5/10 · Genomics/Precision Medicine | Nat Struct Mol Biol; structural CRISPR toolbox for gene therapy applications · DOI: 10.1038/s41594-026-01788-6

Novel Therapeutics

• TR-2026-04-14-015 [PMID 41975140] · Management of borderline resectable NSCLC: narrative review · 5/10 · Treatment Innovation | Clinical review on emerging neoadjuvant immunotherapy for borderline resectable NSCLC · Clin Transl Oncol

Cardiovascular-Metabolic (GLP-1, SGLT2, Cardiometabolic)

• TR-2026-04-14-012 [PMID 41975084] · SR-BI protects against HFpEF by inhibiting T-cell cardiotropism · 5/10 (capped, animal) · Treatment Innovation | EMBO Mol Med; novel immune-endothelial mechanism for HFpEF — major unmet need · DOI: 10.1038/s44321-026-00405-9
• TR-2026-04-14-013 [PMID 41975024] · SGLT2 inhibitors improve eGFR slope independent of proteinuria in Japanese CKD · 5/10 · Diagnostics | Single-center real-world; suggests independent renal protection mechanism · Clin Exp Nephrol

Rare Diseases

• TR-2026-04-14-010 [PMID 41975004] · Rare genetic diseases linked to G-quadruplex-induced replication stress · 6/10 · Genomics/Precision Medicine | Commun Biol review; mechanistic bridge across multiple rare diseases (Fanconi, Bloom), shared therapeutic target · DOI: 10.1038/s42003-026-09966-4
• TR-2026-04-14-011 [PMID 41975025] · Renal morphology in TAFRO and POEMS syndromes: multicenter Japanese study · 6/10 · Diagnostics | Ultra-rare plasma cell disorders with renal involvement; multicenter retrospective, Rare Kidney Disease Research Group · DOI: 10.1007/s10157-026-02864-3

Aging / Longevity

• TR-2026-04-14-014 [PMID 41974728] · Long-lived C. elegans: lifespan extension = expanded decrepitude, not slowed ageing · 5/10 (capped, animal) · Public Health | Nat Commun; high-novelty conceptual reframing of longevity intervention interpretation · DOI: 10.1038/s41467-026-71780-7

💡 UNSOLICITED FINDS

None this run. High-signal out-of-watchlist items were identified and absorbed into watchlist categories (PMID 41975092 was captured under Novel Therapeutics / Rare Diseases).

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 5
• Diagnostics: 5
• Genomics/Precision Medicine: 4
• Early Detection: 2 (partially overlapping Diagnostics)
• Public Health: 2
• Drug Development: 2 (LOW priority)

By evidence maturity:

• Exploratory: 14
• Validated: 4
• Potentially Practice-Changing: 0

By watchlist topic — reviewed / kept (HIGH/STD) / highest score:

By source type:

• Peer reviewed: 20 | Preprint: 0

Topics with zero 8+ articles this run: Early cancer detection, AI/ML diagnostics, Precision oncology, Cardiovascular-metabolic, Aging/longevity, Rare diseases, CBC/ML hematology

🔧 RUN NOTES

• Window expansion: Not triggered (>5 relevant records found in standard window).
• Truncation: AI/ML diagnostics (295 raw results), Immunotherapy/Novel therapeutics (270), Sentinel scan (500), Precision oncology (153), Cardiometabolic (134), Hematologic (105), Rare diseases (162) — all capped at 10 by CRDT recency. Cap logging applied; no silent drops.
• CBC/ML hematology: Only 5 raw results returned (5th-8th+ consecutive sparse run). All 5 reviewed; best score 4/10. This topic likely requires query reformulation in next cycle. Recommend expanding to include morphology-based AI, peripheral blood film AI, and automated differential terms.
• Partial failures: None. All 10 topic searches completed successfully.
• Non-human study cap: Applied to PMID 41975153 (AML HERV-K102, raw 8→capped 5) and PMID 41975084 (HFpEF SR-BI, raw 8→capped 5) and PMID 41974728 (C. elegans aging, raw 7→capped 5). Downstream pipeline should note pre-cap scores.
• Data quality: All articles reviewed from abstract/title metadata only (esummary); no PMC full text accessed this run. Classification confidence appropriately set to medium/high based on availability.
• Rolling note (7-day): CBC/ML hematology has now produced zero HIGH-priority results for 8+ consecutive runs. Aging/longevity consistently noisy with low clinical signal (best 5/10). These patterns should flag for watchlist refinement.